Solid Biosciences Inc. $133.7 Million Initial Public Offering

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc.

The common stock is listed on the Nasdaq Global Select Market under the symbol “SLDB.”

J.P. Morgan, Goldman Sachs & Co. LLC and Leerink Partners acted as Joint-Bookrunners in the offering.

Based in Cambridge, Massachusetts, Solid Biosciences is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick (Picture), counsel Yasin Keshvargar and associate Roohi Gupte. Counsel David R. Bauer and associates Bonnie Chen and Jay Frankel provided intellectual property and technology advice. Partner Mary Conway and associate Anne E. McGinnis provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Deanna Kirkpatrick – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; Roohi Gupte – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Mary Conway – Davis Polk & Wardwell; Anne McGinnis – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman, Sachs & Co.; JP Morgan; Leerink Partners;

Print Friendly, PDF & Email

Author: Ambrogio Visconti